Showing results (1361-1370 of 1,955) with videos related to

Sort By:
Pageof 196
Bone Marrow Transplantation|April 16, 2014
Accuracy of self-reported tobacco use status among hematopoietic SCT patientsS L Ehlers, C A Bronars, C A Patten, et al.
Personality Disorders|February 24, 2015
Personality disorder risk factors for suicide attempts over 10 years of follow-upEmily B Ansell, Aidan G C Wright, John C Markowitz, et al.
The Journal of Investigative Dermatology|November 7, 2017
Epithelial-to-Mesenchymal Stem Cell Transition in a Human Organ: Lessons from Lichen PlanopilarisHisayoshi Imanishi, David M Ansell, Jérémy Chéret, et al.
The American Journal of Medicine|December 3, 2002
Stem cell transplantation for the management of primary systemic amyloidosisMorie A Gertz, Martha Q Lacy, Angela Dispenzieri, et al.
Cell Reports|February 21, 2019
Mass Cytometry Analysis Reveals that Specific Intratumoral CD4<sup>+</sup> T Cell Subsets Correlate with Patient Survival in Follicular LymphomaZhi-Zhang Yang, Hyo Jin Kim, Jose C Villasboas, et al.
Scientific Reports|July 24, 2020
Systemic lipid dysregulation is a risk factor for macular neurodegenerative diseaseRoberto Bonelli, Sasha M Woods, Brendan R E Ansell, et al.
American Journal of Hematology|October 19, 2011
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphomaCarrie A Thompson, Matthew J Maurer, James R Cerhan, et al.
Blood Cancer Journal|July 26, 2012
MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterpartsL S Hodge, S F Elsawa, D M Grote, et al.
Transplantation|January 25, 2005
Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?Irene M Ghobrial, Thomas M Habermann, William R Macon, et al.
Cancer|May 13, 2008
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment GroupDavid J Inwards, Paul A S Fishkin, David W Hillman, et al.
Pageof 196